| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ee0da6543d4d16f0634e75baf2d0d58 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y404-01001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-664
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-664
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 |
| filingDate |
2015-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e67e7ae142c352049a48bd3a7a48986
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6ff23df325b83c18adfbfeb94aa28de |
| publicationDate |
2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9987241-B2 |
| titleOfInvention |
Enzyme conjugate and prodrug cancer therapy |
| abstract |
A method and composition for treating a cancerous tumor in a subject by targeting the tumor's vasculature using an enzyme conjugate comprising a ligand which binds to endothelial cells in the tumor vasculature and converts a prodrug administered to the subject into an anticancer drug in the tumor vasculature. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020032951-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11446365-B2 |
| priorityDate |
2014-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |